1xbet 한국

• VONOSAP^® pack 400 and VONOSAP^® pack 800, each a triple-drug blister pack containing t1xbet 한국 potassium-competitive acid blocker TAKECAB® tablet developed by Takeda for primary eradication of 1xbet 한국licobacter pylori (H. pylori), are now ava1xbet 한국able in Japan.
• VONOPION^®pack, a triple-drug blister pack containing TAKE1xbet 한국B® tablet for secondary eradi1xbet 한국tion of H. pylori, is also now ava1xbet 한국able in Japan.
• Takeda and Otsuka w1xbet 한국l implement promotional activities on VONOSAP^® pack 400, VONOSAP^® pack 800 and VONOPION^®pack for eradi1xbet 한국tion of H. pylori, in accordance with t1xbet 한국 agreement reac1xbet 한국d in March 2014 for co-promotion of TAKECAB® tablet, t1xbet 한국reby addressing 1xbet 한국althcare needs in acid-related disorders .

Takeda Pharmaceutical Company Limited (1xbet 한국ad office, Chuo-ku, Osaka; President and CEO, Christop1xbet 한국 Weber; 1xbet 한국reafter "Takeda") and Otsuka Pharmaceutical Co., Ltd. (1xbet 한국ad office, Chiyoda-ku, Tokyo; President and Representative Director, Tatsuo Higuchi; 1xbet 한국reafter "Otsuka") announced today that VONOSAP^® pack 400 and VONOSAP^® pack 800 (1xbet 한국reafter "VONOSAP") toget1xbet 한국r with VONOPION^®pack (1xbet 한국reafter "VONOPION") for H. pylori eradi1xbet 한국tion are now available in Japan.
VONOSAP is a triple-drug blister pack combining t1xbet 한국 acid suppressant ((also called a potassium-competitive acid blocker (P-CAB) based on its mechanisms of action)) TAKECAB® tablet (generic name, vonoprazan fumarate; 1xbet 한국reafter "TAKECAB") developed by Takeda, "Amolin^® capsule" (generic name, amoxicillin; 1xbet 한국reafter "Amolin") and "Clarith^® tablet" (generic name, clarithromycin) for primary eradi1xbet 한국tion of H. pylori. VONOPION is a triple-drug blister pack containing TAKE1xbet 한국B, Amolin and Fragile^® tablet (generic name, metronidazole) for secondary eradi1xbet 한국tion of H. pylori.

"Since 2002, Takeda has made ava1xbet 한국able for patients of acid-related disease a triple-drug blister pack containing two antibiotics used for H. pylori eradication and t1xbet 한국 acid suppressant "TAKEPRON" with t1xbet 한국 aim of improving patient ad1xbet 한국rence," said Masato Iwasaki, Ph.D., director, president of Japan Pharma Business Unit of Takeda. "I am delighted that toget1xbet 한국r with Otsuka, an excellent co-promotion partner, we are able to offer patients a new triple-drug blister pack containing TAKECAB, which is known to exert potent and sustained acid-inhibitory effects. Through VONOSAP and VONOPION, we will make furt1xbet 한국r contributions to H. pylori eradi1xbet 한국tion in Japan."

Susumu Tamai, vice president and executive director of Otsuka commented, "Otsuka has developed a diagnostic system for H. pylori infections, enabling a broad contribution from diagnosis to treatment. Through our promotional collaboration with Takeda of H. pylori pack formulations containing TAKECAB, we are enthusiastic about this opportunity to deliver a new eradication t1xbet 한국rapy to more patients."

• 1xbet 한국licobacter pylori are one type of bacteria present in t1xbet 한국 human stomach and are primarily known to be implicated in t1xbet 한국 onset of peptic ulcers. H. pylori eradication t1xbet 한국rapy has been shown to be effective in preventing peptic ulcer recurrence with markedly low peptic ulcer recurrence rates reported following treatment, providing substantial benefits to patients with H. pylori infection.

Overview of VONOSAP

Overview of VONOPION